BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35338969)

  • 1. Design and synthesis of Aza-boeravinone derivatives as potential novel topoisomerase I inhibitors.
    Zhou Y; Bai YP; Zhang M; Gao JM; Yang CJ; Zhang ZJ; Deng N; Li L; Liu YQ; Xu CR
    Bioorg Chem; 2022 May; 122():105747. PubMed ID: 35338969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel 7-ethyl-10-fluoro-20-O-(cinnamic acid ester)-camptothecin derivatives as potential high selectivity and low toxicity topoisomerase I inhibitors for hepatocellular carcinoma.
    Bai YP; Yang CJ; Deng N; Zhang M; Zhang ZJ; Li L; Zhou Y; Luo XF; Xu CR; Zhang BQ; Ma Y; Liu YQ
    Biochem Pharmacol; 2022 Jun; 200():115049. PubMed ID: 35469784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
    Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
    Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
    Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
    Khalil OM; Gedawy EM; El-Malah AA; Adly ME
    Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100.
    Zhang M; Fu W; Zhu LZ; Liu XF; Li L; Peng LZ; Kai GY; Liu YQ; Zhang ZJ; Xu CR
    Life Sci; 2022 Dec; 311(Pt A):121105. PubMed ID: 36272467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Synthesis of Arylnaphthalene Lignan Lactone Derivatives as Potent Topoisomerase Inhibitors.
    Chen W; Feng Z; Hu D; Meng J
    Med Chem; 2021; 17(8):856-865. PubMed ID: 32520691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions.
    Kardile RA; Sarkate AP; Borude AS; Mane RS; Lokwani DK; Tiwari SV; Azad R; Burra PVLS; Thopate SR
    Bioorg Chem; 2021 Oct; 115():105174. PubMed ID: 34314913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity.
    Nemr MTM; Sonousi A; Marzouk AA
    Bioorg Chem; 2020 Dec; 105():104446. PubMed ID: 33171405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of 3,4-diarylpyrrole Analogues as Potent Topoisomerase Inhibitors.
    Chen W; Feng Z; He X; Zhao Q; Liang Q
    Med Chem; 2018; 14(5):485-494. PubMed ID: 29485001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II.
    El-Metwally SA; Khalil AK; El-Sayed WM
    Bioorg Chem; 2020 Jan; 94():103492. PubMed ID: 31864673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
    Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments.
    Al-Karmalawy AA; Rashed M; Sharaky M; Abulkhair HS; Hammouda MM; Tawfik HO; Shaldam MA
    Eur J Med Chem; 2023 Nov; 259():115661. PubMed ID: 37482023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New benzothienopyran and benzothienopyranopyrimidine derivatives as topoisomerase I inhibitors: Design, synthesis, anticancer screening, apoptosis induction and molecular modeling studies.
    Khalil NA; Ahmed EM; Zaher AF; Alhamaky SM; Osama N; El-Zoghbi MS
    Bioorg Chem; 2023 Aug; 137():106638. PubMed ID: 37257374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.